IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
Hou, Feng-Qin1; Song, Liu-Wei2; Yuan, Quan2; Fang, Lin-Lin2; Ge, Sheng-Xiang2; Zhang, Jun2; Sheng, Ji-Fang3; Xie, Dong-Ying4; Shang, Jia5; Wu, Shu-Huan6; Sun, Yong-Tao7; Wei, Shao-Feng8; Wang, Mao-Rong9; Wan, Mo-Bin10; Jia, Ji-Dong11; Luo, Guang-Han12; Tang, Hong13; Li, Shu-Chen14; Niu, Jun-Qi15; Zhou, Wei-dong16; Sun, Li16; Xia, Ning-Shao2; Wang, Gui-Qiang1
关键词Quantitative Anti-hbc Chronic Hepatitis b Peg-ifn Treatment Treatment Response Prediction Pretreatment Biomarker
刊名THERANOSTICS
2015
DOI10.7150/thno.10636
5期:3页:218-226
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental
资助者National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project ; National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project
研究领域[WOS]Research & Experimental Medicine
关键词[WOS]VIRUS INFECTION ; ANTIGEN ; LAMIVUDINE ; THERAPY ; SEROCONVERSION ; COMBINATION
英文摘要

A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52 +/- 0.36 vs. 4.19 +/- 0.58, p=0.001; virological response [VR], 4.53 +/- 0.35 vs. 4.22 +/- 0.57, p=0.005; combined response [CR], 4.50 +/- 0.36 vs. 4.22 +/- 0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels >= 30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.

语种英语
所属项目编号30925030 ; 81371819 ; 2012ZX10002005 ; 2011ZX09101-008-06 ; 2012ZX10002006 ; 2013ZX10002005 ; D121100003912002
资助者National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project ; National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project
WOS记录号WOS:000345207600001
Citation statistics
Cited Times:11[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52449
Collection北京大学第一临床医学院_感染疾病科
作者单位1.Henan Prov Peoples Hosp, Dept Infect Dis, Zhengzhou, Peoples R China
2.PLA 81st Hosp, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China
3.Peking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, Beijing 100871, Peoples R China
4.Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510275, Guangdong, Peoples R China
7.Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China
8.Fourth Mil Med Univ, Tang Du Hosp, Dept Infect Dis, Xian 710032, Peoples R China
9.Anhui Med Univ, Affiliated Hosp 1, Dept Infect Dis, Hefei, Peoples R China
10.Second Mil Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai, Peoples R China
11.Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China
12.Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning, Peoples R China
13.Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Peoples R China
14.Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin, Peoples R China
15.Changchun Univ, Affiliated Hosp 1, Ctr Liver Dis, Changchun, Peoples R China
16.Xiamen Amoytop Biotech Co Ltd, Xiamen, Peoples R China
Recommended Citation
GB/T 7714
Hou, Feng-Qin,Song, Liu-Wei,Yuan, Quan,et al. Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon[J]. THERANOSTICS,2015,5(3):218-226.
APA Hou, Feng-Qin.,Song, Liu-Wei.,Yuan, Quan.,Fang, Lin-Lin.,Ge, Sheng-Xiang.,...&Wang, Gui-Qiang.(2015).Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon.THERANOSTICS,5(3),218-226.
MLA Hou, Feng-Qin,et al."Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon".THERANOSTICS 5.3(2015):218-226.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Hou, Feng-Qin]'s Articles
[Song, Liu-Wei]'s Articles
[Yuan, Quan]'s Articles
百度学术
百度学术Similar articles in
[Hou, Feng-Qin]'s Articles
[Song, Liu-Wei]'s Articles
[Yuan, Quan]'s Articles
必应学术
必应学术Similar articles in
[Hou, Feng-Qin]'s Articles
[Song, Liu-Wei]'s Articles
[Yuan, Quan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.